市场的价值判断基本是准确的作者:西北哽临近年底,BD市场反倒火热。12月21日,加科思发布消息:泛KRAS抑制剂JAB-23E73的海外权益卖给了阿斯利康,首付款1亿美元,总里程碑付款19.15亿美元。这两个数字加起来,已经超过亚盛当年授权给武田的奥雷巴替尼,坐上中国小分子药物“BD合同总价”的第一把交椅。但市场似乎并不怎么认可这次交易。消息公布后,加科思股价两天狂泻18个点。不知道的还以为是BD...
Source Link市场的价值判断基本是准确的作者:西北哽临近年底,BD市场反倒火热。12月21日,加科思发布消息:泛KRAS抑制剂JAB-23E73的海外权益卖给了阿斯利康,首付款1亿美元,总里程碑付款19.15亿美元。这两个数字加起来,已经超过亚盛当年授权给武田的奥雷巴替尼,坐上中国小分子药物“BD合同总价”的第一把交椅。但市场似乎并不怎么认可这次交易。消息公布后,加科思股价两天狂泻18个点。不知道的还以为是BD...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.